CANG vs LPSN vs NICE vs AUTL

For growth investors, Autolus Therapeutics plc (AUTL) is the stronger pick with 496.

0% revenue growth year-over-year, versus -52. 7% for Cango Inc. (CANG). Cango Inc. (CANG) offers the better valuation at 5. 7x trailing P/E, making it the more compelling value choice. Analysts rate Cango Inc. (CANG) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Cango Inc.

(CANG) is the cheapest at 5. 7x versus NICE Ltd. at 9. 9x.

Over the past 5 years, Cango Inc.

(CANG) delivered a total return of -14. 2%, compared to -99. 7% for LivePerson, Inc. (LPSN). Over 10 years, the gap is even starker: NICE returned +50. 7% versus LPSN's -97. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), NICE Ltd.

(NICE) is the lower-risk stock at 0. 72β versus Cango Inc. 's 2. 25β — meaning CANG is approximately 211% more volatile than NICE relative to the S&P 500. On balance sheet safety, Cango Inc. (CANG) carries a lower debt/equity ratio of 4% versus 12% for Autolus Therapeutics plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Autolus Therapeutics plc (AUTL) is pulling ahead at 496.

0% versus -52. 7% for Cango Inc. (CANG). On earnings-per-share growth, the picture is similar: Cango Inc. grew EPS 960. 0% year-over-year, compared to 27. 5% for Autolus Therapeutics plc. Over a 3-year CAGR, AUTL leads at 88. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Cango Inc.

(CANG) is the more profitable company, earning 37. 3% net margin versus -21. 8% for Autolus Therapeutics plc — meaning it keeps 37. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CANG leads at 22. 2% versus -23. 9% for AUTL. At the gross margin level — before operating expenses — NICE leads at 66. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for CANG: 459.

2% to $3. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, NICE Ltd.

(NICE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 72)). LivePerson, Inc. (LPSN) carries a higher beta of 2. 05 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NICE: +50. 7%, LPSN: -97. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CANG (Consumer Cyclical) and LPSN (Technology) and NICE (Technology) and AUTL (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: CANG is a small-cap deep-value stock; LPSN is a small-cap quality compounder stock; NICE is a small-cap deep-value stock; AUTL is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.